Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer

Krajewski, Wojciech; Aumatell, Júlia; Subiela, José Daniel; Nowak, Łukasz; Tukiendorf, Andrzej; Moschini, Marco; Basile, Giuseppe; Poletajew, Sławomir; Małkiewicz, Bartosz; Giudice, Francesco Del; Maggi, Martina; Chung, Benjamin I.; Cimadamore, Alessia; Galosi, Andrea Benedetto; Fave, Rocco Francesco Delle; D’Andrea, David; Shariat, Shahrokh F.; Horňák, Jakub; Babjuk, Marko; Chorbińska, Joanna; Teoh, Jeremy Yuen‐Chun; Muilwijk, Tim; Joniau, Steven; Tafuri, Alessandro; Antonelli, Alessandro; Panunzio, Andrea; Álvarez‐Maestro, Mario; Simone, Giuseppe; Mastroianni, Riccardo; Łaszkiewicz, Jan; Lonati, Chiara; Zamboni, Stefania; Simeone, Claudio; Niedziela, Łukasz; Candela, Luigi; Macek, Petr; Contieri, Roberto; Hidalgo, Beatriz Gutierrez; Rivas, Juan Gómez; Sosnowski, Roman; Mori, Keiichiro; Mir, Carmen; Soria, Francesco; González-Padilla, D.A.; Faba, Ó. Rodríguez; Palou, Juan; Ploussard, Guillaume; Rajwa, Paweł; Hałoń, Agnieszka; Laukhtina, Ekaterina; Pradère, Benjamin; Tully, Karl; Burgos, Francisco; Cidre, Miguel Ángel Jiménez; Szydełko, Tomasz

doi:10.1016/j.urolonc.2022.06.008

Cited by 10 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grading is a main aspect of BCa management for clinical decision-making since up to 30% of non-muscle invasive cases consist of high-grade BCa that can progress to muscle invasion as well as develop metastases [ 89 , 90 , 91 , 92 , 93 , 94 ]. Only a few studies evaluated the potential of applying AI technologies to MRI for BCa grading purposes [ 70 , 71 ].…”

Section: Discussionmentioning

confidence: 99%

Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement

Ferro

Falagario

Barone³

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

Artificial intelligence is highly regarded as the most promising future technology that will have a great impact on healthcare across all specialties. Its subsets, machine learning, deep learning, and artificial neural networks, are able to automatically learn from massive amounts of data and can improve the prediction algorithms to enhance their performance. This area is still under development, but the latest evidence shows great potential in the diagnosis, prognosis, and treatment of urological diseases, including bladder cancer, which are currently using old prediction tools and historical nomograms. This review focuses on highly significant and comprehensive literature evidence of artificial intelligence in the management of bladder cancer and investigates the near introduction in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement

Ferro

Falagario

Barone³

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The main established predictors of recurrence are multiple tumors, tumor size, prior recurrence, tumor stage, and histological grade. These factors are used to classify risk in all guidelines, including the JUA guideline [ 13 , 16 , 17 , 18 , 19 ]. Adjuvant therapy, including perioperative intravesical instillation, can be administered in addition to TUR-Bt when treating NMIBC.…”

Section: Discussionmentioning

confidence: 99%

Relationship between Preoperative Pyuria and Bacille Calmette-Guerin Treatment in Intravesical Recurrence after Transurethral Resection of High-Risk, Non-Muscle Invasive, Bladder Carcinoma: A Retrospective Study of Human Data

Tsukamoto

Sazuka

Hattori

et al. 2023

Cancers

View full text Add to dashboard Cite

Some researchers have found that preoperative pyuria is a risk factor for recurrence after transurethral resection of high-risk non-muscle invasive bladder cancer. However, to our knowledge, none have clarified the risks associated with pyuria according to bacille Calmette-Guerin (BCG) treatment status. We retrospectively selected patients with high-risk non-muscle invasive bladder cancer according to Japanese Urological Association guidelines. Pyuria was defined as ≥10 white blood cells per high-powered field. We analyzed recurrence-free rates (RFS) in 424 patients who had and had not undergone BCG treatment. The median duration of follow-up was 45.2 months. According to multivariate analysis, postoperative intravesical BCG induction and preoperative pyuria were independent risk factors for intravesical recurrence in the whole study cohort. We found no significant risk factors for recurrence in the BCG-treated group (n = 179). In the non-BCG-treated group (n = 245), patients with pyuria were much more frequently female and more often had T1 disease than patients without pyuria. According to univariate and multivariate analysis, preoperative pyuria is an independent risk factor for intravesical recurrence. There was no significant difference in the severity of pyuria between the BCG and non-BCG-treated groups. Aggressive BCG treatment may need to be considered in patients with high-risk NMIBC and pyuria.

show abstract

“…Pathological stage and histological grade, concurrent CIS, lymphovascular invasion (LVI) and histological variation play an important role in risk stratification of NIMBC ( 42 ). Tumor stage and grade, tumor status (primary or recurrent), previous intravesical chemotherapy, tumor size (<3cm vs. 3cm), and tumor focality (single vs. multiple) were often used as indicators of the scoring models to predict tumor recurrence ( 43 ). According to the International Collaboration on Cancer Reporting guidelines, apart from the pathological stage and histological grade, the pathological report of BCa specimens obtained by biopsy or transurethral resection should include the status of muscularis propria, histological variation, LVI and T1 substaging ( 44 ).…”

Section: Cooperate With Pathologist To Make Accurate Histopathologica...mentioning

confidence: 99%

Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective

Yang

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

According to the guidelines, transurethral resection of bladder tumor (TURBT) followed by intravesical therapy remains the standard strategy for the management of non-muscle invasive bladder cancer (NMIBC). However, even if patients receive standard strategy, the risk of postoperative recurrence and progression is high. From the clinical perspective, the standard strategy needs to be optimized and improved. Compared to conventional TURBT, the technique of en bloc resection of bladder tumor (ERBT) removes the tumor tissue in one piece, thus following the principles of cancer surgery. Meanwhile, the integrity and spatial orientation of tumor tissue is protected during the operation, which is helpful for pathologists to make accurate histopathological analysis. Then, urologists can make a postoperative individualized treatment plan based on the patient’s clinical characteristics and histopathological results. To date, there is no strong evidence that NMIBC patients treated with ERBT achieve better oncological prognosis, which indicates that ERBT alone does not yet improve patient outcomes. With the development of enhanced imaging technology and proteogenomics technology, en bloc resection combined with these technologies will make it possible to achieve precise diagnosis and treatment of bladder cancer. In this review, the authors analyze the current existing shortcomings of en bloc resection and points out its future direction, in order to promote continuous optimization of the management strategy of bladder cancer.

show abstract

Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer

Cited by 10 publications

References 13 publications

Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement

Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement

Relationship between Preoperative Pyuria and Bacille Calmette-Guerin Treatment in Intravesical Recurrence after Transurethral Resection of High-Risk, Non-Muscle Invasive, Bladder Carcinoma: A Retrospective Study of Human Data

Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective

Contact Info

Product

Resources

About